Actas de congresos
In Vivo Study Of Novel Nanocomposite For Prostate Cancer Treatment
Registro en:
In Vivo Study Of Novel Nanocomposite For Prostate Cancer Treatment. Iop Publishing Ltd, v. 617, p. 2015.
1742-6588
WOS:000358033300001
10.1088/1742-6596/617/1/012001
Autor
Silveira
C. P.; Paula
A. J.; Apolinario
L. M.; Favaro
W. J.; Duran
N.
Institución
Resumen
Because of high occurrence of side effects of conventional anticancer drugs, new therapies have been widely studied, such as the use of non-usual molecules and the association with nanomaterials. In this context, sildenafil is a molecule that has been lately considered as a co-adjuvant in cancer therapy because it inhibits an enzyme with a potential role in tumor progression, phosphodiesterase-5. Taking into account the combination of nanoparticles and sildenafil, we produced systems based on mesoporous silica nanoparticles, Pluronic F-127 and sildenafil as the main therapy for prostate cancer. 617